ctDNA dynamics and prognostic value during first-line treatment of metastatic colorectal cancer: Analysis from the phase 3 PARADIGM study.
Kentaro Yamazaki, Riu Yamashita, Takayuki Yoshino, Kohei Shitara et autres
3573 Background: The phase 3 PARADIGM trial showed overall survival (OS) and tumor response advantages of anti-EGFR (panitumumab, PAN) over anti-VEGF (bevacizumab, BEV) therapy with FOLFOX6 in first-line metastatic colorectal cancer (mCRC) despite similar progression-free survival (PFS), highlighting limitations of imaging-based PFS …
jp (code pays fourni par la source)
0 citations
Journal of Clinical Oncology